哮喘与重症COVID-19的关系:一项全国队列研究
控制社会人口学、基础疾病和疫苗接种后,使用低剂量ICS的成人哮喘患者COVID-19死亡风险与无哮喘者无显著差异,而中/高剂量ICS者死亡和住院风险升高;儿童哮喘患者口服激素疗程数与住院风险增加相关。
要点
- 成人哮喘使用低剂量ICS者COVID-19死亡风险与无哮喘者无显著差异。
- 成人哮喘使用中/高剂量ICS者COVID-19死亡和住院风险升高。
- 儿童哮喘口服激素疗程数越多,COVID-19住院风险越高。
核心结论
- 轻度或控制良好的哮喘患者与无哮喘成人相比,COVID-19住院或死亡风险未显著增加。
- 成人哮喘使用中/高剂量ICS与COVID-19死亡和住院风险升高相关。
- 儿童哮喘口服激素疗程数与COVID-19住院风险增加相关。
研究设计与样本
- 基于英格兰2011年人口普查的Office for National Statistics Public Health Data Asset,关联全科医学提取服务数据、死亡登记和医院 Episode Statistics 入院数据。
- 成人随访从2020年1月1日至2021年9月30日,观察COVID-19住院或死亡;儿童仅纳入住院。
- 队列包含35 202 533名成人和2 996 503名12-17岁儿童。
主要发现
- 控制社会人口学因素、基础疾病和疫苗状态后,使用低剂量ICS的成人哮喘患者COVID-19死亡风险与无哮喘者无显著差异。
- 使用中剂量ICS的成人哮喘患者COVID-19死亡HR为1.18(95% CI 1.14至1.23),高剂量ICS者为1.36(95% CI 1.28至1.44)。
- 使用中剂量ICS的成人哮喘患者COVID-19住院完全调整HR为1.53(95% CI 1.50至1.56),高剂量ICS者为1.52(95% CI 1.46至1.56)。
- 儿童哮喘患者疫情前一年口服激素1个疗程的COVID-19住院HR为2.58(95% CI 1.82至3.66),2个或以上疗程者为3.80(95% CI 2.41至5.95)。
临床怎么用
- 对使用中/高剂量ICS的成人哮喘患者应关注其COVID-19重症风险,加强防护和监测。
- 儿童哮喘患者近期口服激素疗程数多提示COVID-19住院风险较高,需重点管理。
- 轻度或控制良好的哮喘患者无需因COVID-19风险而过度担忧。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We aimed to determine whether children and adults with poorly controlled or more severe asthma have greater risk of hospitalisation and/or death from COVID-19. METHODS: We used individual-level data from the Office for National Statistics Public Health Data Asset, based on the 2011 census in England, and the General Practice Extraction Service data for pandemic planning and research linked to death registration records and Hospital Episode Statistics admission data. Adults were followed from 1 January 2020 to 30 September 2021 for hospitalisation or death from COVID-19. For children, only hospitalisation was included. RESULTS: Our cohort comprised 35 202 533 adults and 2 996 503 children aged 12-17 years. After controlling for sociodemographic factors, pre-existing health conditions and vaccine status, the risk of death involving COVID-19 for adults with asthma prescribed low dose inhaled corticosteroids (ICS) was not significantly different from those without asthma. Adults with asthma prescribed medium and high dosage ICS had an elevated risk of COVID-19 death; HRs 1.18 (95% CI 1.14 to 1.23) and 1.36 (95% CI 1.28 to 1.44), respectively. A similar pattern was observed for COVID-19 hospitalisation; fully adjusted HRs 1.53 (95% CI 1.50 to 1.56) and 1.52 (95% CI 1.46 to 1.56) for adults with asthma prescribed medium and high-dosage ICS, respectively. Risk of hospitalisation was greater for children with asthma prescribed one (2.58 (95% CI 1.82 to 3.66)) or two or more (3.80 (95% CI 2.41 to 5.95)) courses of oral corticosteroids in the year prior to the pandemic. DISCUSSION: People with mild and/or well-controlled asthma are neither at significantly increased risk of hospitalisation with nor more likely to die from COVID-19 than adults without asthma.
引用
- Dolby T, Nafilyan V, Morgan A, et al. Relationship between asthma and severe COVID-19: a national cohort study. Thorax. 2022. PMID: 35354646. doi:10.1136/thoraxjnl-2021-218629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。